Dr. Shamini Selvarajah presented a summary of her studies on Alveolar Soft Part Sarcoma at the 2011 ACMG Annual Clinical Genetics Meeting that took place at the Vancouver Convention Center, Vancouver, BC, Canada. Dr. Selvarajah is one of the dedicated scientists from the Dana Farber Cancer Institute in Boston. They study ASPS relentlessly, aiming to understand the biology of this tumor and develop novel therapies which are in such a need for ASPS patients.
The work presented at the ACMG meeting included the identification of 323 genes which are specifically expressed in Alveolar Soft Part Sarcoma tumors. 207 of these genes are mostly abundant in the primary, and 116 of them are mostly abundant in ASPS metastases of 12 patients whose tumors were analyzed in this study. The 323 genes represent 16 key biological processes, gene signatures, and pathways that can be targeted in future studies.
iCureASPS will continue to support this research at the Dana Farber Cancer Institute through efforts of our Team ASPS participating in the PMC bike ride, and through generous donations from friends and family members of the large ASPS community.
To see the presentation of this study, follow the link – Identification of neural stem cell gene expression signatures associated with disease progression in alveolar soft part sarcoma by integrated molecular profiling
Shamini Selvarajah1,2, Pyne Saumyadipta2, Eleanor Chen1, G. Petur Nielsen3, Glenn Dranoff2, Edward Stack2, Massimo Loda1,2 and Richard Flavin1,2
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115;
Center for Molecular Oncologic Pathology, Dana–Farber Cancer Institute, Boston, MA 02115;
Massachusetts General Hospital, Boston, MA 02114
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)